Figures
Abstract
Objectives
Acquired coagulopathy may be associated with bleeding risk. Approaches to restore haemostasis include administration of coagulation factor concentrates, but there are concerns regarding potential prothrombotic risk. The present study assessed the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) versus activated PCC (aPCC) and recombinant factor VIIa (rFVIIa), using three preclinical animal models.
Methods
The first model was a modified Wessler model of venous stasis-induced thrombosis in rabbit, focusing on dilutional coagulopathy; the second model employed the same system but focused on direct oral anticoagulant reversal (i.e. edoxaban). The third model assessed the prothrombotic impact of 4F-PCC, aPCC and rFVIIa in a rat model of ferric chloride-induced arterial thrombosis.
Results
In the first model, thrombi were observed at aPCC doses ≥10 IU/kg (therapeutic dose 100 IU/kg) and rFVIIa doses ≥50 μg/kg (therapeutic dose 90 μg/kg), but not 4F-PCC 50 IU/kg (therapeutic dose 50 IU/kg). The impact of 4F-PCC (up to 300 IU/kg) on thrombus formation was evident from 10 minutes post-administration, but not at 24 hours post-administration; this did not change with addition of tranexamic acid and/or fibrinogen concentrate. 4F-PCC-induced thrombus formation was lower after haemodilution versus non-haemodilution. In the second model, no prothrombotic effect was confirmed at 4F-PCC 50 IU/kg. The third model showed lower incidence of thrombus formation for 4F-PCC 50 IU/kg versus aPCC (50 U/kg) and rFVIIa (90 μg/kg).
Citation: Ghosh S, Krege W, Doerr B, Mischnik M, Pragst I, Dickneite G, et al. (2021) Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models. PLoS ONE 16(10): e0258192. https://doi.org/10.1371/journal.pone.0258192
Editor: Erin Lavik, University of Maryland Baltimore County, UNITED STATES
Received: January 18, 2021; Accepted: September 21, 2021; Published: October 6, 2021
Copyright: © 2021 Ghosh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting information files.
Funding: This study was funded by, and conducted on behalf of, CSL Behring. All authors are currently or were previously employees of CSL Behring (www.cslbehring.com).
Competing interests: SG, WK, BD, MM, IP and EH are employees of CSL Behring; GD was previously an employee of CSL Behring and reports stocks from CSL during the conduct of the study. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Introduction
A coagulopathic state may result from systemic disorders causing a reduction in coagulation factors (e.g. trauma). In addition, the coagulation response is modulated in patients who are in receipt of anticoagulation therapy (e.g. vitamin K antagonists [VKAs] or direct oral anticoagulants [DOACs]) at a level sufficient to prevent a thrombotic event. In both cases, there is an associated bleeding risk [1,2]. Techniques for haemostatic management of bleeding include controlling blood loss and replenishment of coagulation factors to prevent or ameliorate coagulopathy, and anticoagulant reversal (if applicable) [2,3].
It should be noted that coagulation factors and other haemostatic agents are often used sequentially or in combination in clinical practice [2,4]. Fresh frozen plasma (in conjunction with red blood cells) is one recommendation for the initial management of patients with massive traumatic haemorrhage [2], but it is not routinely recommended in guidelines on anticoagulation reversal, partly due to the fact that its clotting factor content is lower than typical levels in whole blood [5,6]. As such, factor concentrates, with their greater concentrations of clotting factors within a lower administration volume [7,8], have been included in treatment protocols, with some studies indicating similar, or improvements, in patient outcomes versus fresh frozen plasma alone [4,9–11]. Fibrinogen is known to be depleted in trauma [12], and so early administration of fibrinogen concentrate (FCH) is recommended by the Task Force for Advanced Bleeding Care in Trauma [2]; maintenance of a target fibrinogen level is also recommended by the American College of Cardiology when managing DOAC-associated bleeding [3]. Tranexamic acid (TXA) is a further option, with early administration recommended in the initial management of bleeding and coagulopathy [2,3].
Prothrombin complex concentrates (PCCs) can be used to treat trauma-induced bleeding (e.g. where a deficit in clotting factors may be present) and are also frequently used for anticoagulation reversal. PCCs consist of preparations of activated or non-activated vitamin K-dependent coagulation factors (F); non-activated PCCs include 4F-PCCs (containing FII, VII, IX and X) and 3F-PCCs (containing only minimal amounts of FVII alongside FII, IX and X) [13], while activated PCC (aPCC) includes mainly non-activated FII, IX and X, in conjunction with mainly activated FVII [14]. Recombinant activated FVII (rFVIIa) is also available as a stand-alone product, but is not recommended to treat trauma unless all other attempts to control bleeding have failed [2]; it is noted as a treatment option for anticoagulation reversal in some guidelines, but is not routinely recommended as a first-line option [6,15–17].
As with other procoagulants, 4F-PCC use carries a potential risk of “over-correction” of coagulopathy, potentially leading to thromboembolic events (TEE). To date, clinical data available on the safety profile of 4F-PCC in trauma are limited. 4F-PCC is an established clinical treatment for VKA reversal, with TEE risk similar to that of plasma [10,11,18]; data on the thrombotic safety of 4F-PCC in DOAC reversal (which lies outside the licensed indication for 4F-PCC) are more limited [19–22], although animal studies generally show a good safety profile [19–21]. Data from pig models of dilutional coagulopathy have suggested that PCC treatment is associated with improved outcomes (i.e. reduced time to haemostasis, augmented thrombin generation and higher survival rates versus comparators) [23–26], although individual reports suggest that there may be a risk of TEE at a 4F-PCC dose of 50 IU/kg [27].
To further investigate the thrombotic safety of 4F-PCC with respect to other haemostatic agents, we conducted a series of experiments in various animal models. In the first experiment, the thrombotic activities of 4F-PCC, aPCC and rFVIIa were investigated in a model of dilutional coagulopathy followed by induction of venous stasis-induced thrombosis in rabbits using the well-established Wessler model [19,28–31]. The same test agents were also administered to rabbits anticoagulated with the direct FXa inhibitor edoxaban so as to evaluate their potential thrombotic activities in the context of direct oral anticoagulation. Finally, in order to further assess their prothrombotic potential, 4F-PCC, aPCC and rFVIIa were administered to rats using a ferric chloride-induced arterial thrombosis model.
Methods
All animals received care in compliance with the European Convention on Animal Care, and the studies were approved by local governmental authorities (Regierungspraesidium Gießen). The animal ethics approval numbers were V54-19 c 2015 c MR 1 Nr. A 21/2011 and V54-19 c 2015 c MR 1 Nr. 8a-04-35. All health monitoring was conducted by qualified and registered personnel. Animals were monitored at least 3 times daily during general husbandry and continuously during experiment conduct. For rats, anaesthesia was initiated by an intraperitoneal injection and maintained via intravenous (IV) infusion into the lateral tail vein of the ketamine/xylazine mixture. For rabbits, anaesthesia was induced with 5 mg/kg IV ketamine (Ketavet®, Pharmacia GmbH, Erlangen, Germany) and 0.5 mg/kg IV xylazine 2% (Rompun®, Bayer Vital GmbH, Leverkusen, Germany) and maintained with isoflurane (Isofluran CP®, CP-Pharma Handelsgesellschaft GmbH, Burgdorf, Germany). The method of euthanasia employed was an overdose of CO2 or Isofluran for rats and barbiturates (Euthadorm®) for rabbits, respectively.
The severity of all procedures applied as part of this study were categorised to be of low grade as all procedures were conducted under full anaesthesia and therefore warranted to be pain free. In addition, all procedures including anaesthesia were terminal. No animals were terminated prior to the conclusion of the procedure. Sample size was determined based on historical experience with the animal models applied including expected attrition rate, effect size, and data variability.
Dilutional coagulopathy and venous stasis in rabbits
Animals.
Female New Zealand White rabbits 3–4 months old and weighing 2.2–3.2 kg (Manfred Bauer, Neuenstein-Lohe, Germany) received care in compliance with the European Convention on Animal Care, and the study was approved by the local governmental authorities. The animals were housed individually in wire-steel cages at 21–23°C and 50% relative humidity under a 12 h/12 h light-darkness cycle. The animals had free access to tap water and were fed rabbit pellets (Deukanin, Deutsche Tiernahrung Cremer GmbH & Co. KG, Düsseldorf, Germany) ad libitum.
Venous stasis.
Venous stasis was induced 10 minutes after the end of infusion; for analysis of longitudinal response to 4F-PCC, stasis was induced at varying intervals up to 168 hours post-infusion. Any observed thrombi were graded according to a scoring system from 0 to 3, and their wet weights were determined. Thrombus scores were defined as: 0 (no clot), 1 (one or a low number of small clots, too small to determine weights), 2 (not fully occluding clot, with measurable weight) or 3 (fully occluded clot). Histopathological investigations were also performed.
Modified Wessler test.
To assess thrombogenicity, we used a modification of the Wessler model of venous stasis-induced thrombosis in rabbits [28–30], as described previously [19] and illustrated in Fig 1. The primary endpoints of the study were thrombus score (based on number of clots, degree of occlusion and potential for determination of measurable thrombus weight) and thrombus wet weight after venous thrombosis. Secondary endpoints included assessment of histopathology.
(A) 4F-PCC in rabbits with dilutional coagulopathy, using modified Wessler model of venous stasis-induced thrombosis; (B) 4F-PCC in rabbits with edoxaban-induced coagulopathy using modified Wessler model of venous stasis-induced thrombosis; (C) 4F-PCC in rats, using a ferric chloride-induced model of arterial thrombosis. Haemodilution was used only in the experiments indicated. 4F-PCC, 4-factor prothrombin complex concentrate; h, hours; min, minutes; t, time.
For analysis of longitudinal response to 4F-PCC, venous stasis was induced at 10 minutes, 45 minutes, 6 hours, 24 hours, 72 hours and 168 hours post-infusion. Procoagulant effects were determined by exposing the contralateral jugular vein and isolating a segment of approximately 2 cm, causing a complete stasis in the isolated segment. Thirty minutes after stasis induction the vein segment was excised and dissected in sodium citrate solution.
Haemodilution and treatments.
Female New Zealand White rabbits were subjected to two cycles of haemodilution, separated by a 45-minute interval; animals received 15 mL/kg salvaged erythrocytes part way through this interval (Fig 1A). Haemodilution was only used in some experiments; where haemodilution was used, it was performed in advance of any treatment administration. Treatments included 4F-PCC, aPCC, rFVIIa, TXA and FCH. Animals were randomly allocated to treatment groups (n = 5–18 per group). Treatments were administered via IV infusion, with doses selected to range from therapeutic to supratherapeutic. TXA (15 mg/kg) was administered 5 minutes prior to 4F-PCC infusion as an IV bolus, as was FCH (100 mg/kg); FCH administration continued in parallel with 4F-PCC administration.
Haemodilution was conducted as described in [1]. Animals were subjected to haemodilution in phases by withdrawal of 30 mL/kg blood and infusion of 30 mL/kg hydroxyethyl starch (HES; Infucoll® 6% solution; Schwarz Pharma) pre-warmed to 37°C. This procedure was repeated after 45 minutes. After 30 minutes, during the interval between the two cycles of blood withdrawal and HES infusion, the animals received 15 mL/kg salvaged erythrocytes, prepared from withdrawn whole rabbit blood by centrifugation for 10 min at 800×g, washing in normal saline and resuspension in Ringer’s lactate.
4F-PCC (Beriplex®/Kcentra®, CSL Behring GmbH, Marburg, Germany) was reconstituted in water for injection (B. Braun Melsungen AG, Melsungen, Germany) to a final FIX potency of 28 IU/mL, as per label instructions [2], and administered via IV infusion at doses of 50, 100, 200, 300, 400 and 500 IU/kg. 3F-PCC (Bebulin® VH, Baxter Healthcare Corporation, Westlake Village, USA) [3] was reconstituted in sterile water for injection and administered at 300 IU/kg. Activated PCC (Factor Eight Bypassing Activity [FEIBA] Baxter AG, Vienna, Austria) [4] was reconstituted in water for injection and administered at doses of 5, 10, 50, 75 and 100 IU/kg. rFVIIa (NovoSeven®, Novo Nordisk A/S, Bagsværd, Denmark) [5] was reconstituted in histidine diluent and administered at doses of 10, 50, 90, 180 and 300 μg/kg.
TXA (Carinopharm GmbH, Elze, Germany; provided as solution [100 mg/mL]) was administered at a dose level of 15 mg/kg, 5 minutes prior to 4F-PCC infusion as an IV bolus; this was considered a therapeutic dose. FCH (RiaSTAP®, CSL Behring GmbH, Marburg, Germany) was reconstituted in water for injection and a dose of 100 mg/kg was administered as an IV bolus beginning 5 minutes prior to 4F-PCC infusion and continuing in parallel with 4F-PCC administration [6]. Equivalent volumes of isotonic saline [0.9%, Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany] were used in the negative control groups. In rabbits with dilutional coagulopathy, there were 29 groups in total with n = 5–18 per group.
Histopathology.
Following necropsy, the lung, kidney, liver, heart and brain were harvested and fixed in 10% Neutral Buffered Formalin for histopathological analysis. Histopathological investigations (Covance Laboratories, Harrogate, UK) of lung, kidney, liver, heart and brain tissue were conducted for all treatment groups for positive signals of thrombus formation following venous stasis. Tissue was processed and embedded in paraffin wax blocks, and sections with a nominal thickness of 5 μm were stained with haematoxylin and eosin prior to examination. Histopathology was assessed in accordance with the agreed definitive Histopathology Technical Method.
Direct FXa-induced coagulopathy in rabbits
To further evaluate the thrombogenicity of 4F-PCC, we investigated its impact in rabbits undergoing edoxaban anticoagulation, using the modified Wessler model as described above. Specifics of the animals used for these experiments are as above for dilutional coagulopathy, as are details of 4F-PCC, aPCC and rFVIIa preparation, and histopathology.
Study design.
The study design is illustrated in Fig 1B. The primary endpoints were thrombus score in the presence and absence of edoxaban, thrombus wet weight after venous thrombosis and histopathological changes in lungs, kidney, liver, heart and brain tissue.
Treatments and model.
Animals were randomly allocated to treatment groups (n = 5 per group). Edoxaban tosilate hydrate (600 μg/kg) was administered via slow IV bolus at 0 minutes (Fig 1B). The dose level was chosen to reflect therapeutically relevant doses of edoxaban in this model, avoiding excessive anticoagulation [32].
4F-PCC doses of 50 and 300 IU/kg were administered via IV infusion over 15 minutes, starting at 5 minutes (Fig 1B); doses were chosen to include the 4F-PCC dose required to reverse edoxaban-associated bleeding in previous experiments in a rabbit model (i.e. 50 IU/kg) [32], and supra-therapeutic doses expected to elicit a reproducible prothrombotic response in this animal model (i.e. 300 IU/kg) [31].
Edoxaban tosilate hydrate powder (Lixiana®, Daiichi Sankyo Co., Ltd, Tokyo, Japan) was reconstituted in Glucosteril® 5% (Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany) to a final concentration of 300 or 600 μg/mL [7].
4F-PCC (Beriplex®/Kcentra®, CSL Behring GmbH, Marburg, Germany) was prepared as described in the section above, and was administered via the ear vein. Equivalent volumes of isotonic saline (0.9%, Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany) were used as negative control. There were 10 experimental groups with n = 5 per group.
Arterial thrombosis in rats
Study design.
The thrombogenicity of 4F-PCC in comparison with aPCC and rFVIIa was assessed using a ferric chloride (FeCl3)-induced arterial thrombosis model in rats. Primary endpoint was the incidence of thrombus occlusion and time to occlusion.
Animals.
Female CD (Sprague Dawley wildtype) IGS rats 9–12 weeks old and weighing 230–260 g (Charles River, Neuenstein-Lohe, Germany) received care in compliance with the European Convention on Animal Care, and the study was approved by the local governmental authorities. The animals were housed in macrolon cages with wood shavings (J Rettenmaier und Söhne, Rosenberg, Germany) at 20–24°C and 40–50% relative humidity under a 12 h/12 h light-darkness cycle. The animals had free access to tap water and were fed a standard rat diet (Ssniff-Versuchsdiäten, Soest, Germany). Rats were housed under laboratory conditions, after a health examination. Only animals who passed this examination and had no visible signs of illness were used for the study.
Treatment and arterial thrombosis model.
A 1 x 2.5 mm filter paper patch saturated with FeCl3 solution was placed on the carotid artery for a 5-minute period in order to induce thrombosis; varying concentrations of FeCl3 (5%, 7.5%, 10%, and 50% solutions) were initially applied to establish the optimum concentration for use in this study.
4F-PCC was given by intravenous infusion, while aPCC, rFVIIa and saline were administered as a slow IV bolus injection via the jugular vein; infusion time points were 10 minutes prior to thrombus induction for aPCC, and 5 minutes prior to thrombus induction for 4F-PCC and rFVIIa. Isotonic saline (2 mL/kg; 0.9%, Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany) served as the negative control.
When administering triple treatments, a total of 2.24 mL injection volume was used across all groups; part of this volume was the group’s treatment product, while the remaining volume was substituted using isotonic saline. Considering the FeCl3 treatment as t = 0, the three treatments were given at -5, -10 and -15 minutes; for 4F-PCC, isotonic saline was given at -15 and -10 min while 4F-PCC was given at -5 min, while for isotonic saline triple, saline was given at -15, -10 and -5 min. Blood flow was monitored for 60 minutes following FeCl3 patch application, after which blood samples were terminally drawn through puncturing the vena cava. Blood flow in rats was measured with the TS420 Perivascular flow module and using 1.5PSL flow probes (Transonic).
Thrombosis was induced via placement of a filter paper patch saturated with FeCl3 solution on the carotid artery; varying concentrations of FeCl3 were applied in order to induce a sub-maximal incidence of thrombus formation, thus allowing observation of potential pro-coagulatory effects. Both the 5% and 7.5% concentrations of FeCl3 solution achieved a thrombus incidence rate below 100% (20% and 70% for 5% FeCl3 and 7.5% FeCl3, respectively); therefore the 5% FeCl3 concentration was chosen for investigation with the agents, as mostly procoagulant effects were expected. Blood flow was monitored for 60 minutes (Fig 1C) and terminal blood samples were subsequently drawn. 4F-PCC, aPCC or rFVIIa were administered as an IV bolus. There were 7 experimental groups with n = 10 per group.
Statistical analysis
As indicated in the results below, groups were pooled for analysis. Quantitative variables were summarised using the mean and standard deviation/standard error. P-values were calculated by Wilcoxon rank sum-test. Power analysis was done against the t-distribution with a significance level of 0.05. Randomisation of animals to study groups was not used in most experiments. Operators were not blinded during the study. No methods were used to reduce subjective bias.
Results
Dilutional coagulopathy in rabbits: Impact of 4F-PCC, aPCC and rFVIIa
Dose-response for 4F-PCC, aPCC, and rFVIIa.
At the lower end of the dose ranges tested (4F-PCC 50 IU/kg, aPCC 5 IU/kg, rFVIIa 10 μg/kg) we did not detect any thrombus formation when venous stasis was induced (10 minutes after infusion ended; Fig 2). For 4F-PCC, thrombus formation started to be observed at doses of 100 IU/kg or above (Fig 2A); however, thrombus weights were below 50 mg until doses exceeded 400 IU/kg (Fig 2B). At these higher doses, thrombus weight was correlated with thrombus score. At 4F-PCC 500 IU/kg, mean thrombus score was 2.1 (standard deviation [SD] 0.78) and mean thrombus weight was 37.11 mg (SD 48.37). For aPCC, thrombi were observed at doses of 10 IU/kg or above, with thrombus scores of approximately 2 for doses of 50 IU/kg or above (Fig 2C). Thrombus weight was 26.29 mg (SD 26.37) for the 50 IU/kg dose and increased further with increasing dose (Fig 2D). With rFVIIa, thrombi were observed at doses of 50 μg/kg (score 1.33 [SD 0.58]) and above (Fig 2E). Thrombus weights were under 10 mg at rFVIIa 50 μg/kg (7.68 mg [SD 11.55]) but increased to 60.33 mg (SD 9.07) at the 180 μg/kg dose (Fig 2F). At therapeutic doses (i.e. 4F-PCC 50 IU/kg, rFVIIa 90 μg/kg and aPCC 100 IU/kg), we did not observe thrombi with 4F-PCC but did for rFVIIa and aPCC (mean [SD] thrombus scores of 1.60 [0.89] and 2.30 [0.82] respectively). Reflecting thrombus scores of the treatments tested, aPCC was associated with the greatest mean thrombus weight: 89.80 mg (SD 69.82) at 100 IU/kg.
(A) 4F-PCC thrombus score; (B) 4F-PCC thrombus weight; (C) aPCC thrombus score; (D) aPCC thrombus weight; (E) rFVIIa thrombus score; (F) rFVIIa thrombus weight. Data for venous stasis-induced thrombosis 10 minutes after the end of PCC, aPCC or rFVIIa infusion. Figure shows mean (standard deviation). * indicates a therapeutic dose.
Time course of response to 4F-PCC.
The thrombus formation seen at the supratherapeutic dose of 300 IU/kg of 4F-PCC at 10 minutes post-administration (approximate score: 2) was also confirmed at 45 minutes and 6 hours post dosing (Fig 3A). The effects of 4F-PCC were no longer apparent at 24 hours; testing carried out at 1 week (168 hours) post-administration gave a thrombus score of 0. Thrombus weights were generally correlated with thrombus scores (Fig 3B); mean weights at 10 minutes and at 45 minutes were 10.60 mg (SD 6.19) and 17.60 mg (SD 13.85), respectively. Although we noted a further increase in thrombus weight from the 45-minute to the 6-hour time point, the large error (SD) observed at 6 hours does not allow any firm conclusions to be drawn.
(A) thrombus score; (B) thrombus weight. ND, not detectable. Data for venous stasis-induced thrombosis at the indicated timepoints after the end of 4F-PCC (300 IU/kg) infusion. Figure shows mean (standard deviation).
4F-PCC in combination with TXA and/or FCH.
Thrombus scores following a supratherapeutic dose of 4F-PCC (300 IU/kg: 1.82 [SD 0.75]) were in the same range as scores for 4F-PCC in combination with TXA 15 mg/kg (2.00 [SD 0.00]), 4F-PCC in combination with FCH 100 mg/kg (1.60 [SD 0.55]), and 4F-PCC in combination with both TXA, and FCH (0.80 [SD 1.10]; S1 Fig). TXA 15 mg/kg or FCH alone did not lead to detectable thrombus formation. Thrombus weights were as follows: 4F-PCC alone (300 IU/kg: 9.0 mg [SD 9.82]), 4F-PCC with TXA 15 mg/kg (18.0 mg [SD 12.63]), 4F-PCC with FCH 100 mg/kg (4.8 mg [SD 6.38]), 4F-PCC with TXA and FCH (13.4 [SD 28.32]).
4F-PCC in haemodilution.
In animals who had undergone haemodilution (Table 1), thrombus scores and weights with a supratherapeutic dose of 4F-PCC (300 IU/kg: thrombus score 1.40 [SD 0.89], thrombus weight 9.0 mg [SD 9.8]) were similar regardless of whether animals also received 100 mg/kg FCH (thrombus score 0.80 [1.10], thrombus weight 11.4 mg [SD 17.9]; S2 Fig). Thrombus scores and weights were lower in haemodiluted animals compared with non-haemodiluted animals, both in terms of thrombus score (1.4 [SD 0.89] vs 1.8 [SD 0.8] respectively) and weight (9.0 mg [SD 9.8] vs 23.9 mg [SD 22.4] respectively).
(A) 4F-PCC in rabbits with dilutional coagulopathy, using modified Wessler model of venous stasis-induced thrombosis; (B) 4F-PCC in rabbits with edoxaban-induced coagulopathy using modified Wessler model of venous stasis-induced thrombosis; (C) 4F-PCC in rats, using a ferric chloride-induced model of arterial thrombosis.
Histopathology.
No thrombus formation was observed in the kidney, liver, heart or brain. Thrombus formation was not found in the lung in animals receiving 4F-PCC (50 IU/kg). In the lung of animals treated with a supratherapeutic dose of 4F-PCC 300 IU/kg, thrombus formation was recorded, consistent with administration of a prothrombotic agent and the results of the Wessler rabbit model. There was no evidence of thrombus formation until 1.25 hours post-dose. At this timepoint we observed minimal lung thrombi formation (grade 1) in 2/5 animals and grade 3 thrombus formation in 1/5 animals. There was a general decline in thrombus incidence at and after 24.5 hours post-dose.
Direct FXa inhibitor-induced coagulopathy in rabbits: Impact of 4F-PCC
Dose-response for 4F-PCC.
Following administration of saline or 4F-PCC 50 IU/kg, no thrombus formation was observed at 30 minutes (Fig 4A and 4B). When the supratherapeutic dose of 4F-PCC 300 IU/kg was administered, thrombus formation with score 2 was observed in all animals at both 30 minutes and 6 hours, with median (range) thrombus wet weights of 12 (7–18) mg and 22 (7–51) mg, respectively (Fig 4C and 4D), confirming prior results. Thrombus formation was no longer evident at 24 hours (Fig 4C and 4D). Administration of a clinically relevant dose of edoxaban 600 μg/kg prior to 4F-PCC 300 IU/kg significantly inhibited thrombus formation 30 minutes after edoxaban dosing (P = 0.008 for both thrombus score and weight vs saline followed by 4F-PCC 300 IU/kg, Fig 4A and 4B). Some inhibition of thrombus formation was still apparent at 6 hours, but the difference was not significant (P = 0.17 for score, P = 0.21 for weight, Fig 4C); plasma levels of edoxaban were minimal at this time point. No thrombus formation was evident at 24 hours (Fig 4C and 4D). All significantly different comparisons had a statistical power of >90% given a sample size of 5.
(A) Thrombus score and (B) thrombus wet weight at 30 minutes following administration of edoxaban (600 μg/kg) or saline followed by 4F-PCC and venous stasis in rabbits; (C) thrombus score and (D) thrombus wet weight over time following administration of edoxaban 600 μg/kg or saline followed by 4F-PCC (300 IU/kg) and venous stasis in rabbits. Figure shows median (range). **P<0.01.
Histopathological tissue analysis.
No thrombus formation was observed in the kidney, liver, heart or brain. Thrombus formation was not found in the lung in animals receiving 4F-PCC (50 IU/kg). As expected based on previously generated data [19], a supratherapeutic dose of 4F-PCC (300 IU/kg) led to minimal lung thrombi formation (grade 1) in 3/5 animals at 30 minutes and 6 hours. After 24 hours, minimal thrombi (grade 1) were recorded in 3/5 animals, and moderate thrombus formation (grade 3) was recorded in 1/5 animals. The presence of edoxaban 600 μg/kg led to reductions in thrombus frequency across all time points investigated in animals receiving 4F-PCC 300 IU/kg: minimal thrombi (grade 1) recorded in 2/5 animals at 30 minutes, 6 hours and 24 hours post edoxaban dosing.
Arterial thrombosis in rats: Comparison of 4F-PCC, aPCC and rFVIIa
4F-PCC demonstrated a dose-dependent increase in thrombosis incidence, with 50% and 70% of rats developing a thrombotic occlusion within 40 minutes post-dose of 4F-PCC 100 IU/kg and 150 IU/kg, respectively. At 40 minutes post-dose, the incidence of thrombotic occlusion was lower in rats administered 4F-PCC 50 IU/kg (21%) compared with rats administered aPCC 50 U/kg or rFVIIa 90 U/kg (60% in both groups) (Fig 5).
Incidence of thrombosis after 5% FeCl3 injury and treatment with 4F-PCC, aPCC or rFVIIa.
Discussion
The thrombotic safety profile of PCC, aPCC and rFVIIa was assessed using three different animal models; two of these used a modified Wessler model of venous stasis-induced thrombosis in rabbits with dilutional coagulopathy or DOAC-induced coagulopathy, while the third model focused on arterial thrombosis in rats. All the models suggest that 4F-PCC has a low thrombotic potential compared with the other procoagulant agents tested. Our results suggest that prothrombotic risk with clinically relevant doses of 4F-PCC would be low compared with other procoagulant factor concentrates.
We did not see any thrombus formation with 4F-PCC up to the maximum therapeutic dose (50 IU/kg) in the rabbit model of venous stasis-induced thrombosis (including under conditions of haemodilution), while there was evidence of thrombus formation for aPCC and rFVIIa at doses as low as 10 IU/kg and 50 μg/kg, respectively. We observed thrombus formation with supratherapeutic doses of 4F-PCC (≥100 IU/kg); however, equivalent 4F-PCC levels are not expected to be reached in humans when dosing recommendations [33,34] are followed. When we studied the time course of thrombus formation at the supratherapeutic 4F-PCC dose of 300 IU/kg, we found that prothrombotic effects were apparent between 10 minutes and 6 hours following 4F-PCC infusion, but were not detectable thereafter; this demonstrates the transience of 4F-PCC effects on thrombus formation. However, it should be noted that the half-life of 4F-PCC is longer in humans [35] than in rabbits [32], which should be taken into account when considering the duration of potential thrombotic effects in patients.
Various clinical studies have investigated the thromboembolic safety of PCC in acquired coagulopathy (i.e. drug-induced coagulopathy, or coagulopathy occurring as the result of a systemic disorder). Reported risks of TEE are similar for both 4F-PCC and plasma in randomised controlled trials of VKA reversal [18,36–38], although real-world evidence from a retrospective patient chart review suggests that TEE risk may be greater for patients receiving 4F-PCC compared with FFP [39]. Based on retrospective studies and a systematic review, the TEE risk associated with clinical use of 4F-PCC in DOAC-mediated bleeding is low [40–44]. A review of PCC use in acquired coagulopathy noted a good safety profile in a cardiac surgery setting, with TEE incidence ranging from 0 to 6.2% [45], while studies of PCC use in trauma-induced coagulopathy show a TEE risk ranging up to 11.1% for PCC alone or in combination with FCH or FFP (no significant difference was observed compared with either product) [45]. Our results suggest that there is no increase in thrombotic risk when 4F-PCC is used in combination with FCH and/or TXA. Such data are reassuring, as these treatments may be used together in clinical practice [2,4]; however, it should be noted that the use of high-dose PCC (50 IU/kg) in combination with high-dose fibrinogen (100 mg/kg) was associated with increased risk of pulmonary emboli in a pig trauma model compared with PCC monotherapy [26]. Additionally, a risk of TEE has been demonstrated in the same model with high-dose (50 IU/kg) 4F-PCC [27]. 4F-PCC has also been associated with low TEE rates in liver disease-associated coagulopathy (ranging from 0 to 7%) [45]. Overall, TEE rates in cardiac surgery, trauma-induced coagulopathy and liver disease-associated coagulopathy appear to be in line with the background TEE incidence observed for these conditions [45], although there is no systematic data on the use of PCC under these different conditions.
Importantly, prothrombotic risk with a supratherapeutic dose of 4F-PCC (300 IU/kg) is not increased in the context of haemodilution. In haemodilution and in ‘true’ coagulopathy there may be concerns about a disproportionate reduction in coagulation inhibitor levels, which would in turn enhance the thrombogenicity of procoagulant agents. Our results indicate that this is not the case. In fact, thrombus scores were slightly lower in haemodiluted animals vs non-haemodiluted animals, suggesting that thrombotic risk may be offset to some extent by haemodilution. When assessing thrombotic risk associated with PCC administration following edoxaban treatment, no prothrombotic signal was seen with a clinically relevant dose of 4F-PCC (50 IU/kg). The data in the rabbit model of edoxaban-induced coagulopathy are supported by the rat model of FeCl3-induced arterial thrombosis: administration of 4F-PCC (50 IU/kg) was not associated with an increase in thrombus formation incidence versus saline in this setting, indicating that therapeutic doses of 4F-PCC do not increase prothrombotic risk. In contrast, therapeutic doses of aPCC and rFVIIa were both shown to increase the thrombus formation incidence versus saline, which is again in line with the results seen with the rabbit models and indicates that lower doses of aPCC or rFVIIa may be a treatment option in cases of trauma-induced coagulopathy.
It is important to amass data such as those we present here, to inform clinical use as local protocols may vary between trauma centres, and patient injuries are variable–using these model systems we are able to provide standardised evidence of potential risk, and to address the contributions of components of a treatment protocol (TXA, FCH) to overall risk. When speculating on the clinical relevance of our observations, it is important to be mindful of species-specific variations in coagulation, and in pharmacokinetics of PCC clearance [32,35]. One study in a pig model used to evaluate the safety of PCC in trauma suggests that pigs may become hypercoagulable in response to PCC, although this may vary according to dose used [27,46] and also according to co-treatment(s) [26]. ROTEM analysis of traumatised pigs (without PCC use) indicates the emergence of a hypercoagulable state in response to trauma [47], although there are a lack of corresponding data in untraumatised pigs, which hinders data interpretation. In addition, it should be considered that pigs have been reported to display a general tendency to hypercoagulability [48]. Species differences in coagulation profiles support a multi-species approach as there is no animal species available that is similar to humans in all relevant parameters [49]. Another potential limitation of the dilutional coagulopathy model used in the present study, on the other hand, is a lack of tissue injury and resulting tissue factor exposure. While the direct comparison of procoagulant treatments across animal models as applied in the present studies helps to derive conclusions on relative preclinical safety, for full understanding of procoagulant effects and the safety profiles of procoagulants, dedicated clinical trials would be necessary. It should also be noted that a limitation of this analysis is that it covers the results of three different studies, conducted over a number of years in different models, which may introduce some bias due to the different origins of the data.
In summary, these preclinical models of dilutional coagulopathy, edoxaban-induced coagulopathy and arterial thrombosis show a low thrombotic risk associated with 4F-PCC administration in rabbits and rats. 4F-PCC was not associated with thrombus formation at therapeutic doses in these models as opposed to results observed with aPCC or rFVIIa.
Supporting information
S1 Fig. 4F-PCC in combination with tranexamic acid or fibrinogen concentrate.
(A) thrombus score; (B) thrombus weight. Data for venous stasis-induced thrombosis 10 minutes after the end of PCC infusion. 4F-PCC dose was 300 IU/kg, FCH dose was 100 mg/kg and TXA dose was 15 mg/kg. Figure shows mean (standard deviation).
https://doi.org/10.1371/journal.pone.0258192.s001
(TIF)
S2 Fig. 4F-PCC and fibrinogen concentrate following haemodilution.
(A) thrombus score; (B) thrombus weight. Data for venous-stasis induced thrombosis 10 minutes after the end of 4F-PCC infusion. 4F-PCC dose was 300 IU/kg and FCH dose was 100 mg/kg. Figure shows mean (standard deviation).
https://doi.org/10.1371/journal.pone.0258192.s002
(TIF)
Acknowledgments
Medical writing assistance was provided by Meridian HealthComms Ltd and Fishawack Communications Ltd.
References
- 1. Milling TJ Jr., Ziebell CM. A review of reversal of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. Trends Cardiovasc Med. 2019;30(2):86–90. pmid:30952383
- 2. Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019;23(1):98. pmid:30917843
- 3. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017;70(24):3042–67. pmid:29203195
- 4. Innerhofer P, Fries D, Mittermayr M, Innerhofer N, von Langen D, Hell T, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol. 2017;4(6):e258–e71. pmid:28457980
- 5. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev. 2007;21(1):37–48. pmid:17174219
- 6.
ACC 2018: Guidance for anticoagulation reversal: ACC factsheet. [https://www.acc.org/~/media/Non-Clinical/Images/Tools%20and%20Practice%20Support/Mobile%20Resources/ManageAnticoag/B20115-Reversal-Agent-Fact-Sheet.pdf.
- 7. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates—evaluation of safety and thrombogenicity. Crit Care. 2011;15(1):201. pmid:21345266
- 8. Sorensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol. 2010;149(6):834–43. pmid:20456356
- 9. Joseph B, Khalil M, Harrison C, Swartz T, Kulvatunyou N, Haider AA, et al. Assessing the Efficacy of Prothrombin Complex Concentrate in Multiply Injured Patients With High-Energy Pelvic and Extremity Fractures. J Orthop Trauma. 2016;30(12):653–8. pmid:27875491
- 10. Goldstein JN, Refaai MA, Milling TJ Jr., Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–87. pmid:25728933
- 11. Sarode R, Milling TJ Jr., Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–43. pmid:23935011
- 12. Hayakawa M. Dynamics of fibrinogen in acute phases of trauma. J Intensive Care. 2017;5(1).
- 13. Sadeghi N, Kahn D, Sayed D, Hoppenstadt D, Jeske W, Harenberg J, et al. Compositional differences in commercially available prothrombin complex concentrates. Clin Appl Thromb Hemost. 2014;20(3):256–69. pmid:24288386
- 14.
Baxter. FEIBA NF (Anti-Inhibitor Coagulant Complex), Nanofiltered and Vapor Heated 2011 [cited 2016. http://www.feiba.com/us/forms/feiba_nf_pi.pdf.
- 15. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206–32. pmid:26780747
- 16. Frontera JA, Lewin JJ 3rd, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine. Crit Care Med. 2016;44(12):2251–7. pmid:27858808
- 17. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018;154(5):1121–201. pmid:30144419
- 18. Hill R, Han TS, Lubomirova I, Math N, Bentley P, Sharma P. Prothrombin Complex Concentrates are Superior to Fresh Frozen Plasma for Emergency Reversal of Vitamin K Antagonists: A Meta-Analysis in 2606 Subjects. Drugs. 2019;79(14):1557–65. pmid:31401731
- 19. Herzog E, Kaspereit FJ, Krege W, Doerr B, van Ryn J, Dickneite G, et al. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model. Thromb Res. 2014;134(3):729–36. pmid:25084749
- 20. Honickel M, Braunschweig T, Rossaint R, Schochl H, Grottke O. Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma. Transfusion. 2019;59(4):1376–87. pmid:30586470
- 21. Honickel M, Braunschweig T, Rossaint R, Stoppe C, Ten Cate H, Grottke O. Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma. Anesthesiology. 2017;127(5):852–61. pmid:28857806
- 22. Honickel M, Braunschweig T, van Ryn J, Ten Cate H, Spronk HM, Rossaint R, et al. Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model. Anesthesiology. 2015;123(6):1350–61. pmid:26414500
- 23. Dickneite G, Dorr B, Kaspereit F, Tanaka KA. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. J Trauma. 2010;68(5):1151–7. pmid:19996804
- 24. Dickneite G, Pragst I. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. Br J Anaesth. 2009;102(3):345–54. pmid:19168856
- 25. Honickel M, Rieg A, Rossaint R, Braunschweig T, Spronk HM, ten Cate H, et al. Prothrombin complex concentrate reduces blood loss and enhances thrombin generation in a pig model with blunt liver injury under severe hypothermia. Thromb Haemost. 2011;106(4):724–33. pmid:21901227
- 26. Grottke O, Honickel M, Braunschweig T, Reichel A, Schochl H, Rossaint R. Prothrombin Complex Concentrate-induced Disseminated Intravascular Coagulation Can Be Prevented by Coadministering Antithrombin in a Porcine Trauma Model. Anesthesiology. 2019;131(3):543–54. pmid:31180918
- 27. Grottke O, Braunschweig T, Spronk HM, Esch S, Rieg AD, van Oerle R, et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood. 2011;118(7):1943–51. pmid:21670472
- 28. Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis-inducing activity in human serum. Journal of applied physiology. 1959;14:943–6. pmid:13844118
- 29. Giles AR, Johnston M, Hoogendoorn H, Blajchman M, Hirsh J. The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits. Thromb Res. 1980;17(3–4):353–66. pmid:6768160
- 30. Thomas DP. Venous thrombosis and the "Wessler test". Thromb Haemost. 1996;76(1):1–4. pmid:8819241
- 31. Pragst I, Kaspereit F, Dorr B, Dickneite G. Prothrombin complex concentrate (Beriplex P/N) for control of bleeding after kidney trauma in a rabbit dilutional coagulopathy model. Thromb Res. 2010;125(3):272–7. pmid:19913880
- 32. Herzog E, Kaspereit F, Krege W, Doerr B, Mueller-Cohrs J, Pragst I, et al. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. Anesthesiology. 2015;122(2):387–98. pmid:25419685
- 33.
CSL Behring. KCENTRA® Highlights of Prescribing Information [updated September 2014. http://labeling.cslbehring.com/PI/US/Kcentra/EN/Kcentra-Prescribing-Information.pdf.
- 34.
CSL Behring. Beriplex P/N Summary of Product Characteristics. 2016.
- 35. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98(4):790–7. pmid:17938803
- 36. Milling TJ Jr., Refaai MA, Goldstein JN, Schneider A, Omert L, Harman A, et al. Thromboembolic Events After Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate: Exploratory Analyses of Two Randomized, Plasma-Controlled Studies. Ann Emerg Med. 2016;67(1):96–105 e5. pmid:26094105
- 37. Joseph R, Burner J, Yates S, Strickland A, Tharpe W, Sarode R. Thromboembolic outcomes after use of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal in a real-world setting. Transfusion. 2016;56(4):799–807. pmid:26589481
- 38. Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016;116(5):879–90. pmid:27488143
- 39. Maguire M, Fuh L, Goldstein JN, Marshall AL, Levine M, Howell ML, et al. Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department. West J Emerg Med. 2019;20(4):619–25. pmid:31316701
- 40. Allison TA, Lin PJ, Gass JA, Chong K, Prater SJ, Escobar MA, et al. Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients. J Intensive Care Med. 2018:885066618800657. pmid:30244638
- 41. Harrison SK, Garrett JS, Kohman KN, Kline JA. Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibitors versus vitamin K antagonists treated with 4-factor prothrombin complex concentrate. Proc (Bayl Univ Med Cent). 2018;31(2):153–6. pmid:29706805
- 42. Santibanez M, Lesch CA, Lin L, Berger K. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals. J Crit Care. 2018;48:183–90. pmid:30218958
- 43. Tao J, Bukanova EN, Akhtar S. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors. J Intensive Care. 2018;6:34. pmid:29942519
- 44. Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, et al. Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv. 2019;3(2):158–67. pmid:30658963
- 45. Chowdary P, Peralta R.M. Prothrombin complex concentrates in acquired coagulopathy–friend or foe? Drugs of the Future. 2019;44(9):705.
- 46. Mitterlechner T, Innerhofer P, Streif W, Lodl M, Danninger T, Klima G, et al. Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model. J Thromb Haemost. 2011;9(4):729–37. pmid:21255250
- 47. Mulier KE, Greenberg JG, Beilman GJ. Hypercoagulability in porcine hemorrhagic shock is present early after trauma and resuscitation. J Surg Res. 2012;174(1):e31–5. pmid:22172130
- 48. Köstering H, Mast WP, Kaethner T, Nebendahl K, Holtz WH. Blood coagulation studies in domestic pigs (Hanover breed) and minipigs (Goettingen breed). Lab Anim. 1983;17(4):346–9. pmid:6678359
- 49. Siller-Matula JM, Plasenzotti R, Spiel A, Quehenberger P, Jilma B. Interspecies differences in coagulation profile. Thromb Haemost. 2008;100(3):397–404. pmid:18766254